Sylvia Cohen-Kaminsky

List of Publications by Year
in descending order

75 papers	3,414 citations	201674 27 h-index	138484 58 g-index
78 all docs	78 docs citations	78 times ranked	4760 citing authors

#	Article	IF	Citations
1	Endothelial-to-Mesenchymal Transition in Pulmonary Hypertension. Circulation, 2015, 131, 1006-1018.	1.6	441
2	Diagnosis and Classification of 17 Diseases from 1404 Subjects <i>via</i> Pattern Analysis of Exhaled Molecules. ACS Nano, 2017, 11, 112-125.	14.6	386
3	Inflammation in Pulmonary Arterial Hypertension. Chest, 2012, 141, 210-221.	0.8	333
4	Pulmonary Lymphoid Neogenesis in Idiopathic Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 311-321.	5.6	249
5	C-Kitâ€"Positive Cells Accumulate in Remodeled Vessels of Idiopathic Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 116-123.	5.6	176
6	Chemotherapy-Induced Pulmonary Hypertension. American Journal of Pathology, 2015, 185, 356-371.	3.8	149
7	Immune Dysregulation and Endothelial Dysfunction in Pulmonary Arterial Hypertension. Circulation, 2014, 129, 1332-1340.	1.6	141
8	Leptin and regulatory T-lymphocytes in idiopathic pulmonary arterial hypertension. European Respiratory Journal, 2012, 40, 895-904.	6.7	110
9	Targeting of c-kit+ haematopoietic progenitor cells prevents hypoxic pulmonary hypertension. European Respiratory Journal, 2011, 37, 1392-1399.	6.7	85
10	Identification of genomic typing of non-DR3 HLA class II genes associated with myasthenia gravis. Journal of Neuroimmunology, 1993, 47, 115-122.	2.3	76
11	NMDA-Type Glutamate Receptor Activation Promotes Vascular Remodeling and Pulmonary Arterial Hypertension. Circulation, 2018, 137, 2371-2389.	1.6	75
12	Reproducibility, Interrater Agreement, and Age-Related Changes of Fractional Anisotropy Measures at 3T in Healthy Subjects: Effect of the Applied b-Value. American Journal of Neuroradiology, 2008, 29, 1128-1133.	2.4	74
13	p45 NF-E2 regulates expression of thromboxane synthase in megakaryocytes. EMBO Journal, 1997, 16, 5654-5661.	7.8	73
14	T-Helper 17 Cell Polarization in Pulmonary Arterial Hypertension. Chest, 2015, 147, 1610-1620.	0.8	72
15	Cytotoxic Cells and Granulysin in Pulmonary Arterial Hypertension and Pulmonary Veno-occlusive Disease. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 189-196.	5.6	54
16	Chromatin immunoselection defines a TAL-1 target gene. EMBO Journal, 1998, 17, 5151-5160.	7.8	52
17	In situ production of interleukins in hyperplastic thymus from myasthenia gravis patients. Human Pathology, 1991, 22, 461-468.	2.0	50
18	Sustained calcium signalling and caspase-3 activation involve NMDA receptors in thymocytes in contact with dendritic cells. Cell Death and Differentiation, 2011, 18, 99-108.	11.2	48

#	Article	IF	Citations
19	Inflammation in pulmonary hypertension: what we know and what we could logically and safely target first. Drug Discovery Today, 2014, 19, 1251-1256.	6.4	48
20	A Proof of Concept for the Detection and Classification of Pulmonary Arterial Hypertension through Breath Analysis with a Sensor Array. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 756-759.	5.6	40
21	Synergistic induction of interleukin-6 production and gene expression in human thymic epithelial cells by LPS and cytokines. Cellular Immunology, 1991, 138, 79-93.	3.0	39
22	Altered intrathymic T-cell repertoire in human myasthenia gravis. Annals of Neurology, 1997, 41, 731-741.	5.3	38
23	N-acetylcysteine improves established monocrotaline-induced pulmonary hypertension in rats. Respiratory Research, 2014, 15, 65.	3.6	38
24	Prevention of autoimmune attack by targeting specific T-cell receptors in a severe combined immunodeficiency mouse model of myasthenia gravis. Annals of Neurology, 1999, 46, 559-567.	5.3	36
25	Multimodal Imaging Mass Spectrometry to Identify Markers of Pulmonary Arterial Hypertension in Human Lung Tissue Using MALDI-ToF, ToF-SIMS, and Hybrid SIMS. Analytical Chemistry, 2020, 92, 12079-12087.	6.5	33
26	Volatolomics of breath as an emerging frontier in pulmonary arterial hypertension. European Respiratory Journal, 2017, 49, 1601897.	6.7	32
27	Evidence of enhanced recombinant interleukin-2 sensitivity in thymic lymphocytes from patients with myasthenia gravis: possible role in autoimmune pathogenesis. Journal of Neuroimmunology, 1989, 24, 75-85.	2.3	31
28	MicroRNA networks in pulmonary arterial hypertension. Current Opinion in Oncology, 2016, 28, 72-82.	2.4	27
29	Imatinib inhibits bone marrow-derived c-kit+ cell mobilisation in hypoxic pulmonary hypertension. European Respiratory Journal, 2010, 36, 1209-1211.	6.7	25
30	T-cell antigenic sites involved in Myasthenia Gravis: Correlations with antibody titre and disease severity. Journal of Autoimmunity, 1991, 4, 137-153.	6.5	24
31	High IL-6 Gene Expression and Production by Cultured Human Thymic Epithelial Cells from Patients with Myasthenia Gravis. Annals of the New York Academy of Sciences, 1993, 681, 97-99.	3.8	24
32	High recombinant interleukin-2 sensitivity of peripheral blood lymphocytes from patients with Myasthenia Gravis: Correlations with clinical parameters. Journal of Autoimmunity, 1989, 2, 241-258.	6.5	23
33	Circulating regulatory antiâ€“T cell receptor antibodies in patients with myasthenia gravis. Journal of Clinical Investigation, 2003, 112, 265-274.	8.2	21
34	Antibodies to thymic epithelial cells in myasthenia gravis. Journal of Neuroimmunology, 1991, 35, 101-110.	2.3	20
35	In vivo miR-138-5p inhibition alleviates monocrotaline-induced pulmonary hypertension and normalizes pulmonary KCNK3 and SLC45A3 expression. Respiratory Research, 2020, 21, 186.	3.6	20
36	Evidence of endogenous volatile organic compounds as biomarkers of diseases in alveolar breath. Annales Pharmaceutiques Francaises, 2013, 71, 203-215.	1.0	19

#	Article	IF	Citations
37	In vitro interleukin-1 (IL-1) production in thymic hyperplasia and thymoma from patients with myasthenia gravis. Journal of Clinical Immunology, 1991, 11, 268-278.	3.8	17
38	Iron Deficiency in Pulmonary Arterial Hypertension: A Deep Dive into the Mechanisms. Cells, 2021, 10, 477.	4.1	16
39	On-chip hybridization kinetics for optimization of gene expression experiments. BioTechniques, 2008, 44, 109-117.	1.8	15
40	Detecting lung infections in breathprints: empty promise or next generation diagnosis of infections. European Respiratory Journal, 2015, 45, 21-24.	6.7	15
41	Respective Role of Thymus and Muscle in Autoimmune Myasthenia Gravisa. Annals of the New York Academy of Sciences, 1998, 841, 397-406.	3.8	14
42	Half of the Tâ€cell repertoire combinatorial diversity is genetically determined in humans and humanized mice. European Journal of Immunology, 2012, 42, 760-770.	2.9	14
43	Implication of the deacetylase sirtuin-1 on synovial angiogenesis and persistence of experimental arthritis. Annals of the Rheumatic Diseases, 2020, 79, 891-900.	0.9	13
44	Follow-up of soluble interleukin-2 receptor levels after thymectomy in patients with myasthenia gravis. Clinical Immunology and Immunopathology, 1992, 62, 190-198.	2.0	12
45	Functional interaction between PDGFÎ² and GluN2B-containing NMDA receptors in smooth muscle cell proliferation and migration in pulmonary arterial hypertension. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2019, 316, L445-L455.	2.9	12
46	Understanding the Role of CD4+CD25^{high} (So-Called Regulatory) T Cells in Idiopathic Pulmonary Arterial Hypertension. Respiration, 2008, 75, 253-256.	2.6	10
47	Cellular aspects of myasthenia gravis. Immunologic Research, 1988, 7, 189-199.	2.9	9
48	Prospects for a T-cell receptor vaccination against myasthenia gravis. Expert Review of Vaccines, 2005, 4, 473-492.	4.4	9
49	Circulating fibrocytes and pulmonary arterial hypertension. European Respiratory Journal, 2012, 39, 210-212.	6.7	8
50	Circulating regulatory antiâ€"T cell receptor antibodies in patients with myasthenia gravis. Journal of Clinical Investigation, 2003, 112, 265-274.	8.2	8
51	Convergent Strategy to Dizocilpine MK-801 and Derivatives. Journal of Organic Chemistry, 2018, 83, 4264-4269.	3.2	7
52	In vivo preferential usage of TCR V/gb8 in Torpedo acetylcholine receptor immune response in the murine experimental model of myasthenia gravis. Journal of Neuroimmunology, 1995, 58, 191-200.	2.3	6
53	In Situ Production of Interleukins in Hyperplastic Thymus from Myasthenia Gravis Patients. Annals of the New York Academy of Sciences, 1993, 681, 100-102.	3.8	5
54	How does binding of agonist ligands control intrinsic molecular dynamics in human NMDA receptors?. PLoS ONE, 2018, 13, e0201234.	2.5	5

#	Article	IF	Citations
55	T-Cell Receptor Expression in the Thymus from Patients with Myasthenia Gravis. Annals of the New York Academy of Sciences, 1995, 756, 438-440.	3.8	4
56	CXCL13 in Tertiary Lymphoid Tissues: Sites of Production Are Different from Sites of Functional Localization. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 369-370.	5.6	4
57	Trichloroethylene increases pulmonary endothelial permeability: implication for pulmonary venoâ€occlusive disease. Pulmonary Circulation, 2020, 10, 1-4.	1.7	4
58	Chemotherapy-induced pulmonary hypertension: Role of alkylating agents. , 2015, , .		3
59	Rationale for a T Cell Receptor Peptide Therapy in Myasthenia Gravis. Annals of the New York Academy of Sciences, 2003, 998, 320-323.	3.8	2
60	Proliferative Responses to Acetylcholine Receptor Peptides in Myasthenia Gravis. Annals of the New York Academy of Sciences, 1988, 540, 504-505.	3.8	1
61	Identification by genomic typing of non-DR3 HLA class II genes Associated with Myasthenia Gravis. Human Immunology, 1993, 36, 49.	2.4	1
62	Abnormal Immunoregulation Involving the IL-2/IL-2 Receptor Complex in Myasthenia Gravis. Annals of the New York Academy of Sciences, 1993, 681, 283-284.	3.8	1
63	Autoimmunity And Pulmonary Arterial Hypertension: The Role Of Leptin. , 2012, , .		1
64	Olfactory receptors in pulmonary arterial hypertension: A novel pathway of vascular remodeling?. , 2015, , .		1
65	Immune repertoire-based signatures in pre-capillary pulmonary hypertension. , 2018, , .		1
66	Inflammation in Pulmonary Arterial Hypertension. , 2012, , 213-229.		1
67	Responsiveness of myasthenia gravis (MG) lymphocytes to recombinant interleukin 2 (r-IL2). Journal of Neuroimmunology, 1987, 16, 36.	2.3	0
68	Responsiveness of Myasthenia Gravis Lymphocytes to Recombinant Interleukin-2. Annals of the New York Academy of Sciences, 1988, 540, 506-507.	3.8	0
69	Does Circulating IL-17 Identify a Subset of Patients With Idiopathic Pulmonary Arterial Hypertension?: Response. Chest, 2015, 148, e132-e133.	0.8	0
70	LSC Abstract â€“ Glutamatergic signaling through pulmonary vascular NMDA receptors in pulmonary hypertension. , 2015, , .		0
71	In-situmetabolite profiling of remodeled arteries in Pulmonary Arterial Hypertension (PAH) using innovative mass spectrometry imaging (MSI) tools. , 2015, , .		0
72	LSC Abstract â€“ Exploring mechanisms and early detection of pulmonary arterial hypertension via breath and lung vascular cells' volatolomics. , 2016, , .		0

#	Article	IF	Citations
73	NMDA receptor crosstalk with PDGFR-Î² and BMPR2 is involved in smooth muscle cell proliferation in pulmonary arterial hypertension. , 2016, , .		0
74	NMDA receptor activation promotes vascular remodeling and pulmonary arterial hypertension. , 2018, , .		0
75	Fine structural modifications of heparan sulfate sulfation patterns in lung are associated with functional effects in Precapillary Pulmonary Hypertension. , 2018, , .		0